Gabriele Ciranna

Dr. Gabriele Ciranna

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2026 in Reports
Verified
Journal Article
Open access
PDF file
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
Background and Clinical Significance: Iatrogenic atrophy following intralesional corticosteroid injections represents a rare but potentially disfiguring complication, particularly when administered in the facial region for the treatment of inflammatory acne. Unlike conventional post-acne atrophic scarring, corticosteroid-induced tissue loss involves both dermal and subcutaneous compartments, resulting in a clinically distinct presentation that poses significant therapeutic challenges, with no established consensus on optimal management. Case Presentation: We report the case of a 26-year-old Caucasian female (Fitzpatrick phototype III) presenting with severe iatrogenic facial atrophy of the left cheek, resulting from multiple intralesional corticosteroid injections performed by a previous physician for papulo-pustular acne. The condition had been clinically stable for approximately two years at first evaluation. The patient underwent a stepwise multimodal protocol delivered over approximately 18 months (November 2023 to April 2025), combining non-ablative fractional laser remodelling (LightScan—Eufoton), Autologous Regenerative Therapy (ART, Seffiller technique, Seffiline srl), hyperdiluted calcium hydroxylapatite (CaHA—Radiesse, Merz Aesthetics) biostimulation, and additional non-ablative fractional photothermolysis sessions, supported by a topical cosmeceutical protocol. Documented follow-up extended to December 2024, 13 months after the initiation of treatment at our centre. Clinician-assessed severity of the post-acne atrophic scarring component improved from Goodman & Baron Grade 3 to Grade 2. Global aesthetic improvement of the treated area was rated as +2 (“much improved”) on the GAIS, with a patient satisfaction score of 5/5. No validated grading instrument was applied to the subcutaneous volume deficit itself, for which no such instrument is currently available. Conclusions: This case documents the clinical management and favourable outcome of a patient with severe iatrogenic steroid-induced facial atrophy treated with a personalised multimodal protocol. While the observed improvement is encouraging, the single-case design does not permit conclusions regarding the efficacy, reproducibility, or generalisability of this approach. Future controlled studies are needed to determine the therapeutic value of this multimodal strategy for this rare condition.

14 January 2026 in Aesthetic Surgery Journal Open Forum
Verified
Journal Article
Open access
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
ADAnastasia Dafne
Anastasia Dafne
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
MSMelfa Sonia
Melfa Sonia
GNGiovanni Nicoletti
Giovanni Nicoletti
Background: Current diagnostic tools for upper arm laxity assessment—including the pinch test and two-dimensional photographic scales—fail to characterize the underlying tissue composition, leading to inappropriate treatment selection and preventable complications. Objectives: To introduce the Melfa-Anastasia Arm Laxity System (MAALS), a precision medicine framework integrating high-frequency ultrasound (HFUS) biometry with a cylindrical geometric model for objective, compositional assessment of brachial architecture. Methods: MAALS employs a noncontact stand-off technique (HFUS, 18-22 MHz) to measure superficial adipose tissue thickness (SAT) and triceps muscle thickness (M) at the mid-brachial sentinel point. Two dimensionless indices are derived: the adipose saturation percentage (%SAT = SAT/Rtot × 100) and the muscle filling ratio (MFR = M/Rtot), where Rtot is the total brachial radius calculated from arm circumference. Results: Based on preliminary anatomically rational thresholds, MAALS defines five phenotypes (0-4): normotrophic (0), adipose hypertrophy (1), mixed morphology (2), pure cutaneous ptosis with critical vascular risk zone (%SAT < 20%, SAT < 4-5 mm; liposuction contraindicated) (3), and sarcopenic/atrophic (4). Each phenotype carries specific therapeutic indications ranging from prevention to regenerative strategies. Conclusions: MAALS is presented as a conceptual precision medicine framework requiring prospective validation, not as an established clinical standard. By providing objective compositional characterization of brachial architecture, it offers a structured basis for safer, more individualized treatment planning, future multicenter validation studies, and integration with AI-based segmentation technologies. Level of Evidence: 5 (Therapeutic):

26 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Fabrizio MelfaFabrizio Melfa
Fabrizio Melfa
Gabriele CirannaGabriele Ciranna
Gabriele Ciranna
Background and Clinical Significance: Iatrogenic atrophy following intralesional corticosteroid injections represents a rare but potentially disfiguring complication, particularly when administered in the facial region for the treatment of inflammatory acne. Unlike conventional post-acne atrophic scarring, corticosteroid-induced tissue loss involves both dermal and subcutaneous compartments, resulting in a clinically distinct presentation that poses significant therapeutic challenges, with no established consensus on optimal management. Case Presentation: We report the case of a 26-year-old Caucasian female (Fitzpatrick phototype III) presenting with severe iatrogenic facial atrophy of the left cheek, resulting from multiple intralesional corticosteroid injections performed by a previous physician for papulo-pustular acne. The condition had been clinically stable for approximately two years at first evaluation. The patient underwent a stepwise multimodal protocol over approximately 18 months, combining non-ablative fractional laser remodelling (LightScan – Eufoton), Autologous Regenerative Therapy (ART, Seffiller technique, Seffiline srl), hyperdiluted calcium hydroxylapatite (CaHA – Radiesse, Merz Aesthetics) biostimulation, and additional non-ablative fractional photothermolysis sessions, supported by a topical cosmeceutical protocol. Clinician-assessed scar severity improved from Goodman & Baron Grade 3 to Grade 2, and Vancouver Scar Scale score from 4–5/13 to 1–2/13. Global aesthetic improvement was rated as +2 ("Much improved") on the GAIS, with patient satisfaction of 5/5. Conclusions: This case demonstrates that a carefully sequenced multimodal approach combining energy-based devices, biological scaffolds, and biostimulatory agents can achieve substantial and durable correction of iatrogenic steroid-induced facial atrophy, providing a reproducible framework for managing this under-reported and therapeutically challenging condition.